Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Dana-Farber Cancer Institute
Avatar

FLT3 Mutations in AML: What Is the Benefit of Midostaurin for Upfront Use? Is There a Clinical Significance of FLT3 Inhibitors in Relapsed Disease?

By Dana-Farber Cancer Institute FEATURING Richard Stone
By Dana-Farber Cancer Institute FEATURING Richard Stone
256 views
May 28, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Leukemia
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
07:33
ecancer

Epitope Editing Enables Targeted Immunotherapy of AML

Feat. G. Casirati
10:42
ASH 2022 Conference Coverage

Results From the Phase 3 ALPINE Study: Zanubrutinib vs. Ibrutinib in…

Feat. J. Brown
04:14
ecancer

ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for…

Feat. J. Brown
11:05
ASH 2022 Conference Coverage

ASH 2022 Preliminary Safety & Efficacy From the Phase 2 APEX Stu…

Feat. D. DeAngelo
14:22
Dana-Farber Cancer Institute

FLT3 Mutations in AML: What Is the Benefit of Midostaurin for Upfron…

Feat. R. Stone
15:59
Dana-Farber Cancer Institute

What's New in AML: Approach to Relapsed and Refractory Disease

Feat. M. Luskin
12:14
Dana-Farber Cancer Institute

FDA Approval of Duvelisib for CLL

Feat. J. Brown
16:18
Dana-Farber Cancer Institute

What is Clonal Hematopoiesis and Why Does It Matter?

Feat. D. Steensma
05:22
Dana-Farber Cancer Institute

Ask the Experts: How I Treat CLL in 2018 Discussion

Feat. M. Davids
23:36
Dana-Farber Cancer Institute

Approach to Frontline Treatment of CLL in 2018

Feat. M. Davids
12:28
Dana-Farber Cancer Institute

CML Frontline Treatment Choice and Monitoring

Feat. D. DeAngelo
20:53
Dana-Farber Cancer Institute

Advances in the Use of Monoclonal Antibodies for ALL

Feat. D. DeAngelo
75:50
Dana-Farber Cancer Institute

Mapping the Future of Acute Lymphoblastic Leukemia

Feat. D. DeAngelo
11:02
Dana-Farber Cancer Institute

FLT-3 Inhibitors in AML

Feat. R. Stone